Get the free PHYSICIAN ORDERS DROTRECOGIN ALFA (rhAPC), XIGRIS - fhshealth

This document outlines the physician's orders for the administration of Drotrecogin Alfa (rhAPC) to ICU patients with severe sepsis, including treatment criteria, contraindications, dosing, and laboratory

How to fill out physician orders drotrecogin alfa

How to fill out PHYSICIAN ORDERS DROTRECOGIN ALFA (rhAPC), XIGRIS

1. Ensure that the patient meets the eligibility criteria for Drotregotin Alfa (rhAPC).
2. Review the patient's medical history and current medications for potential contraindications.
3. Obtain informed consent from the patient or their legal representative.
4. Document the patient's weight in kilograms, as dosing is dependent on this.
5. Specify the dose as per the recommended guidelines based on the patient's condition.
6. Determine the route of administration (usually intravenous) and ensure proper IV access.
7. Fill out the start time and duration of therapy on the physician's order form.
8. Include monitoring parameters required during treatment, such as vital signs and bleeding risks.
9. Sign and date the physician's order to authorize the treatment.
10. Communicate the order to the nursing staff to ensure timely administration.

Who needs PHYSICIAN ORDERS DROTRECOGIN ALFA (rhAPC), XIGRIS?

1. Patients diagnosed with severe sepsis or septic shock who meet specific criteria for treatment with Drotregotin Alfa (rhAPC).
2. Patients with a high risk of organ dysfunction due to sepsis or septic shock.
3. Patients who are not on anticoagulant therapy or have a high bleeding risk.

People Also Ask about

What is the generic name for Jardiance?

Jardiance is available only as a brand-name medication. The active drug in Jardiance, empagliflozin, is not currently available in a generic form.

What is the generic name for Xigris?

Drotrecogin alfa. Drotrecogin alfa (activated) (Xigris, marketed by Eli Lilly and Company) is a recombinant form of human activated protein C that has anti-thrombotic, anti-inflammatory, and profibrinolytic properties. Drotrecogin alpha (activated) belongs to the class of serine proteases.

What is another name for Xigris?

Drotrecogin alfa (activated) (Xigris, Eli Lilly and Company, Indianapolis, Ind) is a recombinant form of human activated protein C. It was approved by the Food and Drug Administration in the last quarter of 2001 for the reduction of mortality due to severe sepsis in adult patients who are at high risk of death (1).

How much does Drotrecogin alfa cost?

Drotrecogin alfa therapy is expensive with a cost of approximately $42 per mg. The average cost for a 70 kg patient is $7,000 per treatment period. The average cost for a 100 kg patient is $10,000 per treatment period. Therefore, drotrecogin alfa costs approximately $100/kg for the 96-hour treatment period.

Why was Xigris pulled from the market?

"While there were no new safety findings, the study failed to demonstrate that Xigris improved patient survival and thus calls into question the benefit-risk profile of Xigris and its continued use," said Timothy Garnett , M.D., Lilly's Senior Vice President and Chief Medical Officer.

What is the generic name for fosphenytoin?

Cerebyx (fosphenytoin sodium) Injection is an anti-epileptic drug, also called an anticonvulsant, used to prevent or control seizures. Cerebyx is used only for a short time, such as 5 days, when other forms of phenytoin cannot be given.

What is the use of Drotrecogin Alfa?

Drotrecogin alfa (activated) is a new therapeutic agent approved for reduction of mortality in adult patients with severe sepsis. Currently no other treatments are available or pending approval for severe sepsis. Drotrecogin alfa (activated) is a re-combinant form of human activated protein C.

Is Xigris still on the market?

Eli Lilly has thus decided to withdraw the product from the market worldwide. At this stage physicians should not initiate treatment with Xigris in new patients and should stop ongoing treatment.

For pdfFiller’s FAQs

What is PHYSICIAN ORDERS DROTRECOGIN ALFA (rhAPC), XIGRIS?

PHYSICIAN ORDERS DROTRECOGIN ALFA (rhAPC), commonly known as XIGRIS, is a medication used in the management of severe sepsis and septic shock. It is a recombinant form of activated protein C that plays a role in inhibiting clot formation and inflammation.

Who is required to file PHYSICIAN ORDERS DROTRECOGIN ALFA (rhAPC), XIGRIS?

Typically, healthcare providers, including physicians and nurse practitioners, are required to file PHYSICIAN ORDERS for DROTRECOGIN ALFA (rhAPC), XIGRIS, when prescribing the medication for appropriate patients diagnosed with severe sepsis.

How to fill out PHYSICIAN ORDERS DROTRECOGIN ALFA (rhAPC), XIGRIS?

To fill out PHYSICIAN ORDERS DROTRECOGIN ALFA (rhAPC), XIGRIS, the healthcare provider must include patient identification, dosage, administration route, frequency of administration, and duration of treatment. Additionally, any relevant patient history and specific clinical indications should be noted.

What is the purpose of PHYSICIAN ORDERS DROTRECOGIN ALFA (rhAPC), XIGRIS?

The purpose of PHYSICIAN ORDERS DROTRECOGIN ALFA (rhAPC), XIGRIS, is to provide a standardized method for healthcare providers to prescribe this medication as part of the treatment regimen for patients with severe sepsis and associated conditions to reduce organ dysfunction and improve survival rates.

What information must be reported on PHYSICIAN ORDERS DROTRECOGIN ALFA (rhAPC), XIGRIS?

The information that must be reported on PHYSICIAN ORDERS DROTRECOGIN ALFA (rhAPC), XIGRIS includes the patient's full name, medical record number, specific diagnosis, dosage of the medication, administration schedule, any contraindications or allergies, and the healthcare provider's signature.